Fedratinib: 12 agencies, 2021–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 5.2 years, from 13 May 2021 at AWMSG (Wales) to 2026 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2025, recommended by 2026, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 8 of 15 records date from 2023 or later.
4 distinct indication wordings are recorded for fedratinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess fedratinib, on 13 May 2021; G-BA (Germany) did not open a file until 21 Aug 2025 — a wide spread of 4.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 6 years in total.
Restriction is doing real work here: 4 of 14 decisive outcomes narrowed fedratinib to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), G-BA (Germany) and NICE (England) among others.
2 of the 12 agencies here assessed fedratinib more than once, PBAC (Australia) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
fedratinib has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for fedratinib reads 9 recommended, 4 restricted, 1 not recommended and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 21 Aug 2025 | Inrebic — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
| PBAC (Australia) | 2025 | Myelofibrosis (MF) | Not Recommended | source |
| NICE (England) | 20 Nov 2024 | NICE TA1018 | recommended (optimised) | source |
| HAS (France) | 25 Sep 2024 | Re-assessment of SMR and ASMR | SMR moderate · ASMR V | source |
| HIRA (South Korea) | 9 Feb 2023 | 이전에 룩소리티닙으로 치료를 받은 성인환자의 다음 질병과 관련된 비장비대 또는 증상의 치료 - 일차성 골수섬유증 - 진성적혈구증가증 후 골수섬유증 - 본태성혈소판증가증 후 골수섬유증 | reimbursement appropriate | source |
10 further decisions for fedratinib, across 9 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 15 decisions for fedratinib from 12 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.